Premium
The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
Author(s) -
Goessl Carsten,
Katz Leonid,
Dougall William C.,
Kostenuik Paul J.,
Zoog Holly Brenza,
Braun Ada,
Dansey Roger,
Wagman Rachel B.
Publication year - 2012
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2012.06674.x
Subject(s) - denosumab , rankl , medicine , prostate cancer , osteoporosis , cancer , breast cancer , oncology , bone resorption , bone density conservation agents , cancer research , endocrinology , bone mineral , receptor , activator (genetics)
Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal‐related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.